Superiority of alfacalcidol over plain vitamin D in the treatment of glucocorticoid-induced osteoporosis

Rheumatology International

Volumn 24, Issue 2, 2004, Pages 63-70

  Ringe, J D ^a   Dorst, A ^a   Faber, H ^a   Schacht, E ^b   Rahlfs, V W ^c  

^a KLINIKUM LEVERKUSEN   (Germany)

^b BALGRIST UNIVERSITY HOSPITAL   (Switzerland)

^c IDV Datenanalyse und Versuchsplanung   (Germany)

Author keywords

Alfacalcidol; Glucocorticoids; Osteoporosis

Indexed keywords

ALFACALCIDOL; BONDIOL; CALCIUM; COLECALCIFEROL DERIVATIVE; DOSS; GLUCOCORTICOID;

ABDOMINAL DISCOMFORT; ADULT; AGED; ARTHRALGIA; ARTICLE; BACKACHE; BONE DENSITY; BONE MINERAL; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORTICOSTEROID INDUCED OSTEOPOROSIS; DIARRHEA; DRUG WITHDRAWAL; EPIGASTRIC PAIN; FEMALE; FEMUR NECK; FRACTURE; HEADACHE; HUMAN; HYPERCALCEMIA; HYPERCALCIURIA; LONG TERM CARE; LUMBAR SPINE; MAJOR CLINICAL STUDY; MALE; NAUSEA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHEUMATIC POLYMYALGIA; RHEUMATOID ARTHRITIS; RISK REDUCTION; SIDE EFFECT; VERTEBRA FRACTURE;

ADJUVANTS, IMMUNOLOGIC; AGED; CALCIUM; CHOLECALCIFEROL; FEMALE; GLUCOCORTICOIDS; HUMANS; HYDROXYCHOLECALCIFEROLS; MALE; METALS, ALKALINE EARTH; MIDDLE AGED; OSTEOPOROSIS; SPINAL FRACTURES; TREATMENT OUTCOME; VITAMINS;

EID: 1642320904     PISSN: 01728172     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00296-003-0361-9     Document Type: Article

References (36)

1. Schacht E (1999) Rationale for treatment of involutional osteoporosis in women and for prevention and treatment of corticosteroid-induced osteoporosis with alfacalcidol. Calcif Tissue Int 65:317-327
2. Cantorna MT, Hayes CE, DeLuca HF (1998) 1,25-Dihydroxycholecalciferol inhibits the progression of arthritis in murine models of human arthritis. J Nutr 128:68-72
3. DeLuca HF, Cantorna MT (2001) Vitamin D: its role and uses in immunology. FASEB J 15:2579-2585
4. 3 in rheumatoid arthritis patients. Clin Exp Rheumatol 17:453-456
5. Hein G, Oelzner P (2000) Vitamin D-Metabolite bei rheumatoider Arthritis: Befunde-Hypothesen-Konsequenzen. Z Rheumatol 59 [Suppl 1]:I/28-I/32
6. Scharla SH, Schacht E, Bawey S, Kamilli I, Holle D, Lempert UG (2003) Pleiotropic effects of 1α-hydroxyvitamin D (alfacalcidol) in patients with rheumatoid arthritis. Bone [submitted]
7. Van Cleemput J, Daenen W, Geusens P, Dequeker J, van de Werf F, Vanhaecke J (1996) Prevention of bone loss in cardiac transplant recipients. Transplantation 61:1495-1499
8. Reginster JY, Kuntz D, Verdickt W, Wouters M, Guillevin L, Menkès CJ, Nielsen K (1999) Prophylactic use of alfacalcidol in corticosteroid-induced osteoporosis. Osteoporos Int 9:75-81
9. Lakatos P, Nagy Z, Kiss L, Horvath C, Takacs I, Foldes J, Speer G, Bossanyi A (2000) Prevention of corticosteroid-induced osteoporosis by alfacalcidol. Z Rheumatol 59 [Suppl 1]:I 48-52
10. Sambrook PN, Birmingham J, Kelly PJ, Kempler S, Pocock NA, Eisman JA (1993) Prevention of corticosteroid osteoporosis: a comparison of calcium, calcitriol and calcitonin. N Engl J Med 328:1747-1752
11. Sambrook PN, Henderson NK, Keogh A, Macdonald P, Glanville A, Spratt P, Bergin P, Ebeling P, Eisman J (2000) Effect of calcitriol on bone loss after cardiac or lung transplantation. J Bone Miner Res 15:1818-1824
12. Adachi JD, Bensen WG, Bianchi F, Cividino A, Pillersdorf S, Sebaldt RJ, Tugwell P, Gordon M, Steele M, Webber C, Goldsmith CH (1996) Vitamin D and calcium in the prevention of corticosteroid induced osteoporosis: A 3 year follow up. J Rheumatol 23:995-1000
13. Buckley LM, Leib ES, Cartularo KS, Vacek PM, Cooper SM (1996) Calcium and vitamin D3 supplementation prevents bone loss in the spine secondary to low-dose corticosteroids in patients with rheumatoid arthritis. Ann Intern Med 125:961-968
14. 3 (D-hormone) deficiency/resistance with D-hormone and analogs. Osteologie 10:28-39
15. Shane E, Addesso V, Namerow P, Maybaum S, Staron R, Lo S, Zucker M, Pardi S, Mancini D (2002) Prevention of bone loss after cardiac transplantation with alendronate or calcitriol: efficacy and safety. J Bone Miner Res 17:8135
16. American College of Rheumatology Ad Hoc Committee on Glucocorticoid- Induced Osteoporosis (2001) Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Rheum 44:1496-1503
17. Richy F, Reginster JY (2002) Efficacy of D-hormones in primary and corticosteroid-induced osteoporosis: a meta-analysis of their effects on bone mineral density and fracture rate. Osteoporos Int [Suppl 3]:S21
18. 3 on lumbar bone mineral density and vertebral fractures in patients with postmenopausal osteoporosis. Calcif Tissue Int 54:370-376
19. 3. J Bone Miner Metab 10:50-54
20. Tilyard MW, Spears GF, Thomson J, Dovey S (1992) Treatment of postmenopausal osteoporosis with calcitriol or calcium. N Engl J Med 326:357-362
21. Gallagher JC, Fowler SE, Detter JR, Sherman SS (2001) Combination treatment with estrogen and calcitriol in the prevention of age-related bone loss. J Clin Endocrinol Metab 86:3618-3628
22. Boland R (1986) Role of vitamin D in skeletal muscle function. Endocr Rev 7:434-448
23. 3-1α-hydroxylase promoter is regulated by TNFα-in HepG2 and HEK-293 cell lines. Exp Clin Endocrinol Diabetes 109 [Suppl 1]:S26
24. Oelzner P, Muller A, Deschner F, Huller M, Abendroth K, Hein G, Stein G (1998) Relationship between disease activity and serum levels of vitamin D metabolites and PTH in rheumatoid arthritis. Calcif Tissue Int 62:193-198
25. Haug CJ, Aukrust P, Haug E, Morkrid L, Muller F, Froland SS (1998) Severe deficiency of 1,25-dihydroxyvitamin D3 in human immunodeficiency virus infection: association with immunological hyperactivity and only minor changes in calcium homeostasis. J Clin Endocrinol Metab 83:3832-3838
26. 3 prevents the decrease of bone mineral appositional rate in rats with inflammation-mediated osteopenia (IMO). Bone Miner 7:149-158
27. Shiraishi A, Higashi S, Ohkawa H, Kubodera N, Hirasawa T, Ezawa I, Ikeda K, Ogata E (1999) The advantage of alfacalcidol over vitamin D in the treatment of osteoporosis. Calcif Tissue Int 65:311-316
28. Saag KG for the Glucocorticoid-Induced Osteoporosis Intervention Study Group (1998) Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. N Engl J Med 339:292-299
29. Cohen S, Levy RM, Keller M, Boling E, Emkey R, Greenwald M, Zizic T, Wallach S, Sewell K, Lukert B, Achselrod D, Chines A (1999) Risedronate therapy prevents corticosteroid-induced bone loss - a twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum 42:2309-2318
30. Sarkar S, Mitlak BH, Wong M, Stock IL, Black DM, Harper KD (2002) Relationships between bone mineral density and incident vertebral fracture risk with raloxifen therapy. J Bone Miner Res 17:1-10
31. 3 on bone loss by ovariectomy in aged rats. Jpn J Pharmacol 89:255-266
32. 3. J Bone Miner Res 17:1498-1511
33. Wei LJ, Lachin JM (1984) Two-sample asymptotically distribution-free tests for incomplete multivariate observations. J Am Stat Assoc 79:653-661
34. Thall PF, Lachin JM (1988) Analysis of recurrent events: nonparametric methods for random interval count data. J Am Stat Assoc 83:339-347
35. Lachin JM (1992) Some large-sample distribution-free estimators and tests for multivariate partially incomplete data from two populations. Stat Med 11:1151-1170
36. Colditz, GA, Miller JN, Mosteller F (1988) Measuring gain in the evaluation of medical technology: the probability of a better outcome. J Technol Assessment Health Care 4:637-642